首页> 外文期刊>Pathology International >Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity.
【24h】

Age-related EBV-associated B-cell lymphoproliferative disorders: diagnostic approach to a newly recognized clinicopathological entity.

机译:年龄相关的EBV相关的B细胞淋巴抑制性疾病:新公认的临床病理实体的诊断方法。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

EBV is prevalent among healthy individuals, and is implicated in numerous reactive and neoplastic processes in the immune system. The authors originally identified a series of senile or age-related EBV-associated B-cell lymphoproliferative disorders (LPD) bearing a resemblance to immunodeficiency-associated ones, which may be associated with immune senescence in the elderly and which are now incorporated into the 2008 World Health Organization lymphoma classification as EBV-positive diffuse large B-cell lymphoma (DLBCL) of the elderly. This newly described disease is pathologically characterized by a proliferation of atypical large B cells including Reed-Sternberg-like cells with reactive components, which pose a diagnostic problem for pathologists. Clinically, this disease may present with lymphadenopathy, and is often extranodal, frequently involving the skin, gastrointestinal tract, or lung. Onset is usually after the age of 50; the median patient age is 70-79 years, and incidence continues to increase with age, providing additional support to the nosological term of EBV+ DLBCL of the elderly. These patients have a worse prognosis than those with EBV-negative DLBCL or EBV+ classical Hodgkin lymphoma (CHL). The aim of the present review was to summarize the clinicopathological profile of age-related EBV+ LPD and EBV+ Hodgkin lymphoma to facilitate diagnostic approach.
机译:EBV在健康个体中普遍存在,并且涉及免疫系统中的许多反应性和肿瘤过程。作者最初鉴定了一系列老年人或年龄相关的EBV相关的B细胞淋巴抑制性疾病(LPD),其与免疫缺陷相关的相似性,这可能与老年人的免疫衰老有关,现在已纳入2008年世界卫生组织淋巴瘤分类为eBV阳性弥漫性大B细胞淋巴瘤(DLBCL)的老年人。该新描述的疾病是通过非典型大B细胞的增殖,包括具有反应性分量的芦苇 - 斯得人样细胞的非典型大型B细胞的疾病,这为病理学家构成了诊断问题。临床上,这种疾病可能存在淋巴结病,通常是外骨,经常涉及皮肤,胃肠道或肺。发病通常在50岁之后;中位数患者年龄为70-79岁,随着年龄的增长,发病率持续增加,为老年人的EBV + DLBCL的姿态术语提供了额外的支持。这些患者的预后更差,而不是EBV阴性DLBCL或EBV +典型霍奇金淋巴瘤(CHL)。本综述的目的是总结年龄相关的EBV + LPD和EBV + Hodgkin淋巴瘤的临床病理概况,以促进诊断方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号